ACLARION INC
NASDAQ: ACONW (Aclarion Inc)
Kemas kini terakhir: 16 jam lalu0.029
0.01 (35.51%)
| Penutupan Terdahulu | 0.021 |
| Jumlah Dagangan | 70,421 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -10,789.22% |
| EPS Cair (TTM) | -6.58 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 78.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 47.32% |
| Nisbah Semasa (MRQ) | 14.17 |
| Aliran Tunai Operasi (OCF TTM) | -8.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.60 M |
| Pulangan Atas Aset (ROA TTM) | -45.78% |
| Pulangan Atas Ekuiti (ROE TTM) | -74.07% |
AISkor Stockmoo
| Nilai 43% | -0.4 |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Pulangan atas Modal info | NA |
| Trend Perolehan info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa | NA |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Kekuatan Aliran info | NA |
| Persediaan Teknikal info | NA |
| Corak Lilin info | NA |
| Aliran Jangka Sederhana info | NA |
| Sentimen 29% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Pegangan info | NA |
| Sentimen Berita info | NA |
| Wang Pintar 29% | -0.8 |
| Kedudukan jual singkat +16.8% dari 31 Aug hingga 30 Oct 2026, 7.1 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Aliran Institusi info | NA |
| Keadaan pasaran dan sektor menggalakkan. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor mengatasi prestasi pasaran. | |
| Hanya satu tonggak mempunyai bacaan yang jelas, jadi skor tidak berubah. | |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | NA |
| Tiada aliran jelas bagi jangka pendek, sederhana dan panjang. info | |
| Tiada isyarat jelas daripada sokongan dan rintangan. info | |
| Skor Akhir | -0.39 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Bercampur | Menurun |
| Health Information Services (Global) | Bercampur | Menurun | |
| Stok | Aclarion Inc | - | - |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| ACONW | - | - | - | - | -0.4 |
| CARL | 477 M | - | - | 6.29 | 1.6 |
| SY | 166 M | - | - | 0.770 | -2.9 |
| OTRKP | - | - | - | - | -2.9 |
| TEM | 10 B | - | - | 19.68 | -0.1 |
| HQY | 8 B | - | 34.21 | 4.05 | 0.0 |
|
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Captrust Financial Advisors | 30 Sep 2026 | 63,400 |
Tiada data dalam julat masa ini.
Institusi
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 81,593 | 7.1 |
| 15 Oct 2026 | 73,843 | 4.2 |
| 30 Sep 2026 | 67,490 | 5.6 |
| 15 Sep 2026 | 66,327 | 27.1 |
| 31 Aug 2026 | 69,875 | 8.3 |
| 14 Aug 2026 | 231,797 | 4.2 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Oct 2026 | Yahoo Finance |
Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +61.91% and +0.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 27 Oct 2026 | Yahoo Finance |
HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates
HCA (HCA) delivered earnings and revenue surprises of +7.12% and +2.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 22 Oct 2026 | Yahoo Finance |
Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of casesNociscan also spared patients the needles, added cost, and recovery time that is often associated with… |
| 20 Oct 2026 | Yahoo Finance |
Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discographyCLARITY trial expanded to eleven clinical sites… |
| 13 Oct 2026 | Yahoo Finance |
Aclarion to Present at the 20th Annual LD Micro Main Event
BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Aclarion is scheduled to present on Tuesday… |
| 08 Oct 2026 | Yahoo Finance |
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment paceInitial readout timing to be updated by year-end based on demonstrated Q4 enrollment increasesOverall trial duration remains on track BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE)… |
| 29 Sep 2026 | Yahoo Finance |
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical researchCLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical… |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |